Eculizumab in gemcitabine-induced thrombotic microangiopathy: experience of the French thrombotic microangiopathies reference centre

BACKGROUND: Gemcitabine is a broadly prescribed chemotherapy, the use of which can be limited by renal adverse events, including thrombotic microangiopathy (TMA). METHODS: This study evaluated the efficacy of eculizumab, a monoclonal antibody targeting the terminal complement pathway, in patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Grall, Maximilien, Daviet, Florence, Chiche, Noémie Jourde, Provot, François, Presne, Claire, Coindre, Jean-Philippe, Pouteil-Noble, Claire, Karras, Alexandre, Guerrot, Dominique, François, Arnaud, Benhamou, Ygal, Veyradier, Agnès, Frémeaux-Bacchi, Véronique, Coppo, Paul, Grangé, Steven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8293501/
https://www.ncbi.nlm.nih.gov/pubmed/34284729
http://dx.doi.org/10.1186/s12882-021-02470-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8293501/
https://www.ncbi.nlm.nih.gov/pubmed/34284729
http://dx.doi.org/10.1186/s12882-021-02470-3

Ejemplares similares